Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Opioid-Related Disorders

• Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)
• Ketamine for OUD and Suicidal Ideation in the ED
• Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl
• Oral Buprenorphine as a Novel Low-dose Induction Strategy for Opioid Use Disorder
• Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
• Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
• Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy
• Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion
• Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants
• Impact of Tramadol Addiction On Dental Anesthesia Success
• Symptom-inhibited Fentanyl Induction
• Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
• Measuring Acute Drug Demand in Humans
• Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE)
• Treating Polysubstance Use Using a Novel Digital Technology
• The Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults
• Cannabis and Opioid Use Disorder
• E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
• Sublingual Dexmedetomidine for Treating Opioid Withdrawal
• Personalization of Opioid Prescription Following Orthognathic Surgery
• Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations
• OMAR Opioid Use Disorder
• Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
• Tau PET Imaging in Opioid Use Disorder
• Novel Induction to Buprenorphine/Naloxone
• A Clinical Trial to Assess Pharmacokinetic Profiles and Safety of IVL3004
• Duloxetine Impact on Postoperative Pain Control and Outcomes
• Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)
• STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis
• Open Label Comparison of Injectable Buprenorphine ( Brixadi®) and Naltrexone (Vivitrol®) for Opioid Use Disorder
• Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder
• High Dose BUP Induction in the Emergency Department (ED)
• A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.
• Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication
• Reduced Opioid Prescription After Laparoscopic Hysterectomy
• Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing
• Suvorexant for Opioid/Stimulant Co-use
• Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use
• Evaluating Buspirone to Treat Opioid Withdrawal
• Assessing Optimal XR-Buprenorphine Initiation Points in Jail
• Endocannabinoids, Stress, Craving And Pain Effects (ESCAPE) Study
• Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure
• A Double-blind, Randomized, Placebo-controlled Comparison of TAU vs Split Daily Methadone Dosing for Pain Among MMP
• Low-dose Buprenorphine Initiation of Opioid Use Disorder
• Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study
• Detecting Drugs of Abuse Via Exhaled Breath Samples Using Differential Mobility Spectrometry
• A Phase II Study of the O'Neil Long Acting Naltrexone Implant in Opioid Dependent Persons
• Medication-assisted Treatment for Injecting Drug Users in Vietnam
• Opioid Reduction Toolkit Reduces Opioids Prescribed and Consumed
• Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual
• Toward Zero Prescribed Opioids for Outpatient General Surgery
• Reducing Pain and Opioid Use With CBD
• Study of LYN-014 in Individuals With Opioid Use Disorder Who Are Stable on Methadone Therapy
• Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use
• A Safety Study of AZD4041 in Healthy Volunteers
• Postpartum MDMA Co-occurring PTSD and OUD
• A Safety Study of AZD4041 in Healthy Volunteers
• KAP for Depression in Abstinent Opioid Users
• Olanzapine in OUD Patients
• Extended-release Pharmacotherapy for Opioid Use Disorder
• Evaluating the Safety of Acute Baclofen in Methadone-maintained Individuals With Opiate Dependence.
• Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl
• Evaluation of the Interactions of Cannabidiol (CBD) With Morphine
• Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms
• Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
• Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP
• Cariprazine for Comorbid Cocaine and Opioid Use Didorder
• A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder
• Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder
• Ketamine for OUD and Comorbid Depression (OUDCD)
• Assessing a Clinically-meaningful Opioid Withdrawal Phenotype
• Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder
• Opioid/Benzodiazepine Polydrug Abuse: Aim 3
• Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users
• Opioid Use Disorder Treatment Linkage at Sexual Health Clinics Using Buprenorphine
• Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder
• The Effect of Buprenorphine Continuation for Patients With Opioid Use Disorder
• Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder
• A Phase 1, Two Part Study Investigating the Safety, Tolerability and Pharmacokinetics of KNX100 in Healthy Volunteers
• Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments
• OLP to Manage Pain in TJA: A Feasibility Study
• Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder
• Pharmacokinetic and Safety Study of Naltrexone Release From Subcutaneous BICX104 Pellets Compared to Vivitrol Injections
• Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder
• Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose
• Young Houston Emergency Opioid Engagement System
• INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit
• Buprenorphine Induction for Fentanyl Dependent Opioid Users
• PROUD Study - Preventing Opioid Use Disorders
• Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD
• Feasibility of Pediatric Emergency Department-Initiated Treatment for Adolescents With Opioid Use Disorder
• Pharmacokinetic Study of Vivitrol in Healthy Participants
• Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections
• Cannabidiol in Opioid Use Disorder and Chronic Pain
• HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis
• Neuroimaging and CBD for Heroin Use Disorder
• Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders
• Virginia Opioid Treatment-Emergency Department
• Providing Suboxone and PrEP Using Telemedicine
• Oral Pregabalin as Preemptive Analgesia in Abdominal Hysterectomy
• Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
• The Effect of Chronic Pain on Delay Discounting in Methadone Patients
• Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
• Clinical Trials of Multivalent Opioid Vaccine Components
• Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder
• A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants
• A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder
• INDV-2000 First in Human
• Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail
• A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
• Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans
• Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder
• EXHIT ENTRE Comparative Effectiveness Trial
• An Innovative Intervention for OUD Treatment
• Biased Opioid Agonists for Treatment of Opioid Withdrawal in OUD
• Opioid Treatment Program (OTP)-Pharmacy Collaboration for Methadone Maintenance Treatment
• Examining the Role of the Orexin System in Sleep and Stress in Persons With Opioid Use Disorder
• Buprenorphine Loading in the Emergency Department
• Dual-Orexin Antagonism as a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder
• Oral Cannabidiol for Opioid Withdrawal
• Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder
• Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder
• Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder
• Overlapping Buprenorphine Initiation (in Opioid Physical Dependence)
• Emergency Department-Initiated Buprenorphine Validation Network Trial
• Perioperative Ketamine in Opioid-Tolerant Patients Undergoing Lumbar Spine Surgery
• Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults
• Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating Women
• Use of a GLP-1R Agonist to Treat Opioid Use Disorder
• Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine
• Using rTMS to Explore Neural Mechanisms of Stress-Induced Opioid Use
• Ketamine for the Treatment of Opioid Use Disorder and Depression
• Safety and Preliminary Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People With Opioid Use Disorder
• Adjunctive Effects of Psilocybin and Buprenorphine
• Medication Maintenance Therapy in Community Pharmacy Settings
• Single Ascending Dose Study of ALA-1000
• A Prospective, Randomized Trial of the Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post-Operative Opioid Use Disorder Symptoms
• SUBLOCADE Rapid Initiation Extension Study
• Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment
• Oxytocin, Stress, Craving, Opioid Use Disorder
• The Analgesic Efficacy of Continuous Sub-fascial Bupivacaine Infusion and Lidocaine Patches in Post-cesarean Patients With Opiate Use Disorder: A Comparative Efficacy Analysis
• Oral Abuse Potential Study of Nalbuphine
• Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification
• SUBLOCADE Rapid Initiation Study
• Neurobehavioral Mechanisms of Choice in Opioid Use Disorder
• The Kentucky Viral Hepatitis Treatment Study
• Slow-Release Oral Morphine for the Treatment of Opioid Use Disorder
• Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19
• Acute Pain Management in Patients on Opioid Replacement Therapy
• Medication Treatment for Opioid Use Disorder in Expectant Mothers
• Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study
• Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study
• Rapid Initiation of Drug Treatment Engagement
• An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder
• Opioids and Smoking Cessation
• Evaluation of Intranasal Naltrexone and Naloxone
• Reducing the Abuse of Opioids in Drug Users
• Pharmacologically-based Strategies for Opioid Substitution Therapy During Pregnancy
• Pain Management Following Sinus Surgery
• Virginia Opioid Overdose Treatment InitiatVE
• Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction
• OLANI PK/Safety Study in Healthy Volunteers
• Community Studies of Long Acting Buprenorphine (CoLAB)
• Medical Management of Sleep Disturbance During Opioid Tapering
• Cannabidiol as Adjunctive Treatment for Opioid Use Disorder
• Pain Control Following Sinus Surgery
• Medication Maintenance Therapy in Community Pharmacy Settings
• Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology
• Impact of Lofexidine on Stress, Craving and Opioid Use
• Study of a Novel Subcutaneous Depot Formulation of Buprenorphine
• Comparison of Three Opioid Detoxification Treatment Regimens
• Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery
• XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept
• Improving Office Based Treatment of Opioid Use Disorder With Technology
• HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)
• CBT4CBT for Office Based Buprenorphine
• Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy
• Can Simplified and More Detailed Instructions Affect Post-Operative Narcotic Consumption
• Buspirone for Opioid Tapering
• Feasibility of the Utilization of Buprenorphine in the Emergency Room to Treat Clinical Opioid Withdrawal
• Nasal Human Abuse Potential of PTI-821
• Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder
• Relieving Acute Pain (RAP) Study: A Pilot Study
• Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation
• Evaluation of Doxazosin to Alter the Abuse of Oxycodone
• Houston Emergency Opioid Engagement System
• A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.
• Comparison of Naloxone Pharmacokinetics
• A Trial of Directly Observed and Long-term Varenicline
• Facilitating Rapid Naltrexone Initiation
• Smoking Cessation Interventions for People Living With HIV in Nairobi, Kenya
• Gabapentin Regimens and Their Effects on Opioid Consumption
• Postoperative and Opioid Free Anesthesia
• Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures
• Maternal Buprenorphine-naloxone Treatment and the Infant
• Patient Driven Recovery With Nalmefene and Coaching
• Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up
• Effect of Buprenorphine/Naloxone Continuation on Pain Control and Opioid Use
• Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075
• A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic
• A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders
• Medication Development for Opioid and Alcohol Abuse
• Brain Dopaminergic Signaling in Opioid Use Disorders
• Buprenorphine in the Emergency Department
• Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder
• Onsite Buprenorphine Treatment at Syringe Exchange Programs
• Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder
• Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder
• A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults
• A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults
• Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy Volunteers
• Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol
• Opioid Dependence Treatment Therapies in Pregnancy
• Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings
• Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection
• A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse
• Stimulant Oxytocin Study
• Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence
• Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia
• Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings
• Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants
• A Tailored, Peer-delivered Intervention to Reduce Recurring Opioid Overdoses
• Open-Label Treatment Extension Study
• Long-acting Naltrexone for Pre-release Prisoners
• Smoking Cessation & Opioid Dependence Treatment Integration
• Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction
• Single-dose, Study of RBP-6000 in Opioid Dependent Individuals
• Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers
• Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain
• Buccal Versus Injectable Naloxone: a Phase I Healthy Volunteer Study
• Phase II Pharmacokinetics Study of CAM2038
• Comparative Evaluation of PUSPENs and C&Cs
• Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL
• Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence
• NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical Study
• Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder
• Immediate Postpartum Nexplanon Placement in Opioid Dependent Women
• Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence
• Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone
• Influence of Dexmedetomidine and Lidocaine on Opioid Consumption in Laparoscopic Intestine Resection
• A Multiple Dose Opioid Challenge Study
• Medication-Assisted Treatment for Youth With Substance Use Disorders
• Project BEST: Buprenorphine Entry Into Substance Abuse Treatment
• Pharmacokinetic Evaluation of Intranasal and Intramuscular Naloxone in Healthy Volunteers
• Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder
• Oxytocin Treatment of Opioid Dependence
• Improving Treatment Outcomes for Prescription Opioid Dependence
• Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans
• Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)
• Buprenorphine Group Medical Visits in Primary Care
• The Safety of Using Buprenorphine With Naloxone in a Buccal Film to Initiate Treatment of Opioid Dependent Subjects
• Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder
• Comparing Opium Tincture (OT) With Methadone for Medication-assisted Treatment of Opioid Use Disorder
• Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers
• Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence
• Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia
• Study of the Treatment of Experimental Pain in Buprenorphine Maintained Persons With Chronic Musculoskeletal Pain
• The Comparison of Stress Response to Rapid Opioid Detoxification Applying Different Methods of Opioid Antagonism
• Interim Buprenorphine: Leveraging Medication + Technology to Bridge Delays in Treatment Access
• The Effects of Minocycline in Opioid-maintained Patients
• Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine
• A Randomized Trial of Interim Methadone and Patient Navigation Initiated in Jail
• Biomarkers of Injectable Extended Release Naltrexone Treatment
• Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone
• Safety and Efficacy of Pre-incisional Intravenous Ibuprofen to Reduce Postoperative Pain and Opioid Dependence After Posterior Cervical or Lumbar Instrumented Spine Surgery
• Desvenlafaxine in Opioid-Dependent Patients
• Buprenorphine Treatment for Opioid Dependence
• A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants
• Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)
• Oxytocin in Opiate Dependence: A Pilot Study of the Effects of Intranasal Oxytocin on Emotional Processes and Stress Responses in Patients With Opiate Dependence
• Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder
• Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population
• Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment
• Cocaine Opioid Oxytocin Option - Limited
• Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry
• Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse
• Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women
• Clinical Efficacy and Serum Proteomic Profiling of Suan-Zao-Ren Tang for Sleep Disturbance During Methadone Maintenance
• Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults
• Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study
• Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence
• Improving Buprenorphine Detoxification Outcomes With Isradipine
• Nalrexone Facilitated Discontinuation of Buprenorphine
• Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone
• Clomiphene Citrate for the Treatment of Low Testosterone Associated With Chronic Opioid Pain Medication Administration
• Testosterone Replacement for Male Opioid Agonist Maintained Patients
• Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia
• Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
• Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence
• A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse
• Dane County Drug Court Study for Addicted Offenders
• Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain Patients
• Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients
• A Drug Treatment for Cocaine Users Who Are Also on Methadone Maintenance Treatment
• Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users
• Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers
• Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects
• Neurocognitive Effects of Opiate Agonist Treatment
• Methadone Oxytocin Option
• Completion of OST - a Prospective Study
• Acute Effects of Cortisol on Heroin Craving in Opioid Dependence (Ghost-Basel)
• Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway
• Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects
• Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence
• An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects
• Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients
• Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance
• Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans
• Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo
• Transfer of Subjects From Subutex/Suboxone to RBP-6300
• Pilot Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients
• The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence
• HIV, Buprenorphine, and the Criminal Justice System
• A Clinical Study To Characterize The Pharmacokinetics And The Effects Of Food On Oxycodone In Healthy Volunteers
• Aprepitant Effects in Intravenous Heroin Dependence
• Pioglitazone to Treat Opioid Withdrawal Symptoms
• Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT
• A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration
• Study to Assess Longer-term Opioid Medication Effectiveness (SALOME)
• Pilot Study of Varenicline to Treat Opioid Dependence
• Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone
• Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia
• Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users
• Improved Strategies for Outpatient Opioid Detoxification
• A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery
• Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants
• An Assessment of Fentanyl Dose Requirements in Opioid-maintained Individuals
• Study to Test the Safety and Efficacy of Cannabidiol as a Treatment Intervention for Opioid Relapse
• Drug-Drug Interaction Study Between Telaprevir and Buprenorphine
• Re-Treatment Study of Probuphine in Opioid Addiction
• Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals
• Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations
• ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids
• Combined Therapy of Methadone and Dextromethrophan
• Medications Development for Drug Abuse Disorders
• Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail
• Naloxone Methadone Combination (NAMEKO)
• A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals
• A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction
• Treatment for Opioid Dependent Offenders
• Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults
• Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy
• Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users
• Dronabinol Naltrexone Treatment for Opioid Dependence
• Opiate Detoxification Using the Combined Hemoperfusion-hemodialysis
• Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents
• Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
• Aprepitant Effects on Oxycodone Response
• Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions
• Efficacy of Computer Delivered Community Reinforcement Approach (CRA) (Bup II)
• Models of Screening, Brief Intervention With a Facilitated Referral to Treatment (SBIRT) for Opioid Patients in the Emergency Department
• Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan
• Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients
• ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals
• Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects
• Treatment Study Using Depot Naltrexone (1/6) Philadelphia Coord/Data Mgmt Site
• Aripiprazole for Prevention of Relapse to Cocaine Use in Methadone-Maintenance Patients
• Study of Probuphine in Patients With Opioid Dependence
• A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence
• Relapse Prevention to Reduce HIV Among Women Prisoners
• Depot Naltrexone Treatment of Opioid Dependent Parolees
• Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse
• Drug Discrimination in Methadone-Maintained Humans Study 2
• Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate Abusers
• Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444)
• Treatment of Opioid Dependent Patients With Suboxone: Acceptability & Safety Data From Real Life Scenario (Study P05603)
• Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED)
• Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal
• Effective Treatment for Prescription Opioid Abuse
• Abuse Liability of Suboxone Versus Subutex
• Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse
• Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial
• Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)
• ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence
• Anxiety in Recovering Opiate Dependence
• Safety and Tolerability of Buprenorphine/Naloxone Film Strips
• Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone
• Clinical Trial of Integrated Treatment for Pain and Opioid Dependence
• Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence
• A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)
• A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED)
• Levetiracetam (Keppra) Tolerability in Cocaine Abusing Methadone-maintained Patients.
• Clinical Efficacy of Disulfiram in LAAM-Maintained Cocaine Abusers
• Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
• Cocaine Withdrawal and Pharmacotherapy Response
• Buprenorphine as a Treatment in Opiate Dependent Pain Patients
• Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction
• The Discriminative Effects of Tramadol in Humans
• Memantine as a Supplement to Naltrexone in Treating Heroin Dependence
• SSRI and Buprenorphine
• Study of Buprenorphine Maintenance Treatment for Opioid Dependence in Primary Care
• Buprenorphine's Dose Response Curve
• Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence
• Substance Abuse Pre-Treatment Screening Study
• Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients
• HIV Risk Reduction and Drug Abuse Treatment in Iran
• The Effects of Pharmacotherapy on Brain Mechanisms Underlying Cocaine Dependence.
• HIV Risk Reduction and Drug Abuse Treatment in Malaysia
• Treatment of Polydrug-Using Opiate Dependents During Withdrawal
• Buprenorphine Maintenance for Opioid-Addicted Persons in Jail and Post-Release
• Methadone Maintenance & HIV Risk in Ukraine
• Opioid Maintenance Medications Comparison Study
• Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence
• Assessment of Tramadol as a Treatment for Opioid Addiction
• Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia
• Clonidine for Relapse Prevention in Buprenorphine-Maintenance Patients
• Combined Behavioral and Pharmacologic Treatment of Polydrug Abuse
• RCT Comparing Methadone and Buprenorphine in Pregnant Women
• Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users
• The German Project of Heroin Assisted Treatment of Opiate Dependent Patients
• Insomnia and Drug Relapse Risk
• Medication Adherence Therapy for Opioid Abusing Pain Patients
• Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1
• Lofexidine for Inpatient Opiate Detox
• The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration
• Disulfiram for Treating Cocaine Dependence in Individuals Maintained on Methadone
• Addiction Treatment in Russia: Oral vs. Naltrexone Implant
• Dextromethorphan, Gabapentin, and Oxycodone to Treat Opioid-Induced Hyperalgesia
• Effects of Post-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals
• Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals
• Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
• Buprenorphine as a Treatment for Individuals Dependent on Analgesic Opioids
• Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals - 8
• Naltrexone Implants vs. MMT Among Inmates in the Norwegian Correctional Services
• Science-Based Treatment for Opioid-Dependent Adolescents
• NAOMI: A Study to Compare Medically-prescribed Heroin With Oral Methadone in Chronic Opiate Addiction
• Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users
• Prescription Opioid Effects in Abusers Versus Non-Abusers
• ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997])
• Pharmacogenetics of Disulfiram for Cocaine
• Abuse Potential of Buprenorphine/Naloxone
• HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a MMT Group.
• Effectiveness of Lofexidine to Prevent Stress-Related Opiate Relapse During Naltrexone Treatment - 1
• Tramadol to Reduce Opioid Withdrawal Symptoms
• Fluoxetine to Reduce Cocaine Use in Cocaine and Opioid Addicts
• Opioid Agonist and Antagonist Effects on Opioid Dependence
• Addition of Naltrexone to Methadone Taper
• Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence
• Blockade Efficacy of Buprenorphine/Naloxone For Opioid Dependence
• Assessing Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid Abusers
• Effectiveness of Tiagabine for Cocaine Dependence in Methadone-Maintained Individuals - 1
• Memantine and Naltrexone Treatment for Opioid Dependence
• Buprenorphine and Integrated HIV Care Evaluation
• Buprenorphine/Naloxone - Facilitated Rehabilitation for Opioid Dependent Adolescents - 1
• Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules - 1
• Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1
• Lofexidine for Opiate Withdrawal - 1
• Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1
• Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14
• Buprenorphine and Naloxone Combination Study - 10
• Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1
• Buprenorphine Dose Escalation Trial for Treatment of Non-Dependent Opiate Users - 2
• Buprenorphine/Naloxone for Opiate-Dependence Treatment - 1
• Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice
• Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7
• Buprenorphine Maintenance for Opiate Dependence - 6
• Evaluation of L-alpha-acetylmethadol (LAAM) in Methadone Patients - 5
• Effects of Buprenorphine and Naloxone in Opiate Addicts - 4
• Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3
• Trial of Buprenorphine/Naloxone for Opiate Dependence - 2
• Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients - 1
• Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10
• Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9
• Evaluation of Liquid vs. Tablet Buprenorphine - 6
• Activity Monitoring Assessment of Opiate Withdrawal - 4
• Comparison of Buprenorphine and Methadone - 3
• Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6
• Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5
• Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4
• Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3
• Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2
• Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1
• Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1
• Buprenorphine Maintenance Dose Schedule and Treatment Setting - 2
• Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1
• Combining Behavioral Treatment With Agonist Maintenance - 1
• Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3
• Feasibility Study of Take-Home LAAM Medication - 3
• Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2
• Buprenorphine Combination Tablet Feasibility - 1
• Novel Medications for Opiate Detoxification - 4
• A Laboratory Model for Heroin Abuse Medications - 8
• Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide - 16
• Effects of Combined Alcohol and Nitrous Oxide Intake - 15
• Effects of Combined Sevoflurane and Nitrous Oxide Inhalation - 14
• Effects of Alcohol History on Effects of Sevoflurane and Nitrous Oxide - 13
• Effects of Behavioral Contingencies on Effects of Nitrous Oxide - 12
• Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations - 11
• Role of Instructions in Nitrous Oxide Effects and Choice - 10
• Effects of Alcohol History on Effects of Nitrous Oxide - 9
• Reinforcing Effects of Brief Exposures to Nitrous Oxide - 8
• Differential Acute Tolerance Development to Effects of Nitrous Oxide - 7
• Isoflurane at Subanesthetic Concentrations - 6
• Effects of Nitrous Oxide: A Dose-Response Analysis - 5
• Lack of Acute Tolerance Development to Effects of Nitrous Oxide - 4
• Effects of Subanesthetic Concentrations of Isoflurane/Nitrous Oxide - 3
• Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2
• Effects of Subanesthetic Concentrations of Nitrous Oxide - 1
• Effects of Dynorphin 1-13 on Heroin Addiction - 1
• Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone
• Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence. - 22
• Buprenorphine Pharmacology Related to Addiction Treatment - 21
• Temporal Discounting Delayed Outcomes on Opioid-Dependent Outpatients - 20
• Buprenorphine Detoxification - BBDVI - 19
• Buprenorphine Pharmacology Related to Addiction Treatment - 18
• Alternate Day Buprenorphine Administration, Phase XII - 17
• Alternate Day Buprenorphine Administration, Phase XI - 16
• Alternate Day Buprenorphine Administration, Phase X - 15
• Alternate Day Buprenorphine Administration, Phase IX - 14
• Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13
• Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12
• Buprenorphine Detox With Two Types of Treatment. BBD II - 11
• Buprenorphine Detox With Two Types of Treatment. BBD I - 10
• Alternate-Day Buprenorphine Administration. Phase VIII - 9
• Alternate-Day Buprenorphine Administration. Phase VII - 8
• Alternate-Day Buprenorphine Administration. Phase VI - 7
• Alternate-Day Buprenorphine. Phase V - 6
• Alternate-Day Buprenorphine Administration. Phase IV - 5
• Alternate-Day Buprenorphine Administration. Phase II - 4
• Alternate-Day Buprenorphine Administration. Phase I - 3
• Gradual Vs. Rapid Buprenorphine Detoxification - 2
• Buprenorphine Dose Alteration Study - 1
• Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1
• Buprenorphine Dosing Interval - 5
• Methadone/Buprenorphine Cross-Over Study - 4
• Multicenter Clinical Trial of Buprenorphine - 3
• Clinical Rescue Protocol - 2
• Buprenorphine Maintenance Protocol - 1
• Buprenorphine Maintenance for Opioid Addicts - 3
• Buprenorphine Maintenance for Opioid Addicts - 2
• Buprenorphine Maintenance for Opioid Addicts - 1
• Neurobiology of Opioid Dependence: 5 - 5
• Neurobiology of Opioid Dependence: 4 - 4
• Neurobiology of Opioid Dependence: 3 - 3
• Neurobiology of Opioid Dependence: 2 - 2
• Neurobiology of Opioid Dependence: 1 - 1